Endocannabinoid system targeted therapeutics market {Roots Analysis}

Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

Key Market Insights

§  More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that target the human endocannabinoid signaling system

§  The pipeline features a variety of marketed / clinical stage therapies, being investigated for a wide range of target disease indications and designed for administration via different routes

§  The geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countries

§  Despite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseases

§  The growing interest in this field is also reflected by the 170+ partnerships that have been signed in the last five years, involving both international and indigenous stakeholders, across different geographical marketplaces

§  Presently, North American companies seem to be consolidating their presence indigenously, mostly through strategic acquisitions; key value drivers behind such deals include product and geographical expansion

§  Future market size, based on revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across a variety of therapeutic areas, target receptors and key geographical regions

For more information, please visit “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“

Table of Contents

1.         PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Neuropharmacology and Working Mechanism of the Endocannabinoid System

3.3.       Potential Therapeutic Applications of Cannabinoids

3.4.       Legal Aspects and Regulations

3.5.       Existing Challenges

3.6.       Future of Cannabinoid Therapies

4.         MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

4.1.       Chapter Overview

4.2.       Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline

4.2.1.    Analysis by Phase of Development

4.2.2.    Analysis by Target Therapeutic Area

4.2.3.    Analysis by Route of Administration

4.2.4.    Analysis by Dosing Frequency

4.2.5.    Analysis by Target Receptor

4.2.6.    Grid Analysis: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor

4.3.       Endocannabinoid System Targeted Therapeutics: List of Developers

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size and Geographical Location

4.4.       List of Cannabis Suppliers

5.         COMPANY PROFILES

5.1.       Chapter Overview

5.2.       GW Pharmaceuticals

5.2.1.    Company Overview

5.2.2.    Financial Information

5.2.3.    Endocannabinoid Targeting Therapeutics Portfolio

5.2.4.    Recent Developments and Future Outlook

5.3.       Corbus Pharmaceuticals

5.3.1.    Company Overview

5.3.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.3.3.    Recent Developments and Future Outlook

5.4.       Tilray

5.4.1.    Company Overview

5.4.2.    Financial Information

5.4.3.    Endocannabinoid Targeting Therapeutics Portfolio

5.4.3.2.             Recent Developments and Future Outlook

5.5.       Pure Green

5.5.1.    Company Overview

5.5.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.6.       Tetra Bio-Pharma

5.6.1.    Company Overview

5.6.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.6.3.    Recent Developments and Future Outlook

5.7.       Botanix Pharmaceuticals

5.7.1.    Company Overview

5.7.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.7.3.    Recent Developments and Future Outlook

5.8.       Kalytera Therapeutics

5.8.1.    Company Overview

5.8.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.8.3.    Recent Developments and Future Outlook

5.9.       Therapix Biosciences

5.9.1.    Company Overview

5.9.2.    Endocannabinoid Targeting Therapeutics Portfolio

5.9.3.    Recent Developments and Future Outlook

5.10.     Zelira Therapeutics

5.10.1. Company Overview

5.10.2. Endocannabinoid Targeting Therapeutics Portfolio

5.10.3. Recent Developments and Future Outlook

5.11.     Avicanna

5.11.1. Company Overview

5.11.2. Financial Information

5.11.3. Endocannabinoid Targeting Therapeutics Portfolio

5.11.4. Recent Developments and Future Outlook

5.12.     GB Sciences

5.12.1. Company Overview

5.12.2. Financial Information

5.12.3. Endocannabinoid Targeting Therapeutics Portfolio

5.12.4. Recent Developments and Future Outlook

6.         ACADEMIC GRANTS ANALYSIS

6.1.       Chapter Overview

6.2.       Scope and Methodology

6.3.       Endocannabinoid System Targeted Therapeutics: List of Grants Awarded by National Institutes of Health (NIH)

6.3.1.    Analysis by Year of Grant Award

6.3.2.    Analysis by Amount Awarded

6.3.3.    Analysis by Administering Institute Center

6.3.4.    Analysis by Funding Institute Center

6.3.5.    Analysis by Support Period

6.3.6.    Analysis by Funding Institute Center and Support Period

6.3.7.    Analysis by Type of Grant Application

6.3.8.    Analysis by Purpose of Grant Award

6.3.9.    Analysis by Grant Mechanism

6.3.10. Word Cloud Analysis: Emerging Focus Areas

6.3.11. Analysis by Study Section Involved

6.3.12. Popular NIH Departments: Analysis by Number of Grants

6.3.13. Analysis by Types of Recipient Organizations

6.3.14. Prominent Program Officers: Analysis by Number of Grants

6.3.15. Popular Recipient Organizations: Analysis by Number of Grants

6.3.16. Regional Analysis of Recipient Organizations

7.         PARTNERSHIPS AND COLLABORATIONS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Endocannabinoid Targeted Therapeutics: List of Partnerships and Collaborations

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Type of Partnership and Target Disease Indication

7.3.4.    Analysis by Year of Partnership and Type of Partner

7.3.5.    Most Active Players: Analysis by Number of Partnerships

7.3.6.    Regional Analysis

7.3.7.    Intercontinental and Intracontinental Agreements

8.         MERGERS AND ACQUISITIONS

8.1.       Chapter Overview

8.2.       Acquisition Models

8.3.       Endocannabinoid Targeted Therapeutics: Mergers and Acquisitions

8.3.1.    Cumulative Year-wise Trend

8.3.2.    Analysis by Type of Acquisition

8.3.3.    Year of Acquisitions and Deal Financials

8.3.4.    Geographical Analysis of Mergers and Acquisitions

8.3.5.    Ownership Change Matrix

8.3.6.    Most Active Players: Analysis by Number of Acquisitions

8.3.7.    Key Value Drivers

8.3.8.    Valuation Analysis: Acquisition Deal Multiples

9.         DRUG DEVELOPMENT STRATEGY ANALYSIS

9.1.       Chapter Overview

9.2.       Scope and Methodology

9.3.       Strategies Adopted by Late-Stage Drug Candidate Developers

10.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1.     Chapter Overview

10.2.     Forecast Methodology and Key Assumptions

10.3.     Global Endocannabinoid Targeted Therapeutics Market, 2020-2030

10.4.     Global Endocannabinoid Targeted Therapeutics Market: Individual Product Sales Forecasts

10.4.1. EPIDIOLEX® (GW Pharmaceuticals)

10.4.1.1. Target Patient Population

10.4.1.2. Sales Forecast

10.4.2. Sativex® (GW Pharmaceuticals)

10.4.2.1. Target Patient Population

10.4.2.2. Sales Forecast

10.4.3. PPP011 (Caumz)

10.4.3.1. Target Patient Population

10.4.3.2. Sales Forecast

10.4.4. Lenabasum

10.4.4.1. Target Patient Population

10.4.4.2. Sales Forecast

10.4.5.  CannEpil™

10.4.5.1. Target Patient Population

10.4.5.2.  Sales Forecast

10.5.     Global Endocannabinoid System Targeted Therapeutics Market: Focus on CB1, CB2 and TRPV1 Receptors

10.6.     Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2020-2030

10.6.1. Endocannabinoid System Targeted Therapeutics Market in North America, 2020-2030

10.6.2. Endocannabinoid System Targeted Therapeutics Market in Europe, 2020-2030

10.6.3. Endocannabinoid System Targeted Therapeutics Market in Asia-Pacific, 2020-2030

10.6.4. Endocannabinoid System Targeted Therapeutics Market in Rest of the World, 2020-2030

10.7.     Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030

10.7.1. Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2020-2030

10.7.2. Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2020-2030

10.7.3.  Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030

10.7.4. Global Endocannabinoid System Targeted Therapeutics Market for Pain Disorders, 2020-2030

10.8.     Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration

10.8.1.  Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030

10.8.5.  Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2020-2030

11.        CONCLUDING REMARKS

12.        EXECUTIVE INSIGHTS

12.1.     Chapter Overview

12.2      Zelira Therapeutics US           

12.2.1.  Company Snapshot

12.2.2.  Interview Transcript: Oludare Odumosu, Chief Executive Officer

12.3.     GB Sciences

12.3.1. Company Snapshot

12.3.2. Interview Transcript: Andrea Small-Howard, Chief Scientific Officer

12.4.     Tetra Bio-Pharma

12.4.1. Company Snapshot

12.4.2. Interview Transcript: Steeve Néron, Chief Operating Officer

12.5      Vireo Health    

12.5.1.  Company Snapshot

12.5.2.  Interview Transcript: Stephen Dahmer, Chief Medical Officer

13.        APPENDIX 1: TABULATED DATA

14.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com